STOCK TITAN

Virpax Pharmaceuticals Announces Reverse Stock Split

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)

Virpax Pharmaceuticals (NASDAQ: VRPX) has announced a 1-for-25 reverse stock split effective March 20, 2025. The company's common stock will begin trading on a split-adjusted basis on March 21, 2025, maintaining its VRPX symbol on the Nasdaq Capital Market.

The reverse split will reduce outstanding shares from approximately 31,062,581 to 1,242,504. Stockholder ownership percentages will remain unchanged except for fractional shares. The split will proportionally adjust the number of shares issuable through equity awards and warrants, including their exercise prices.

This strategic move aims to achieve compliance with Nasdaq's minimum bid price requirement of $1.00 per share and attract a broader investor base. Stockholders approved the split at a January 15, 2025 special meeting, granting the Board discretion for a ratio between 1-for-2 and 1-for-240.

Virpax Pharmaceuticals (NASDAQ: VRPX) ha annunciato un'operazione di reverse stock split 1 per 25 che entrerà in vigore il 20 marzo 2025. Le azioni ordinarie dell'azienda inizieranno a essere scambiate su base rettificata il 21 marzo 2025, mantenendo il simbolo VRPX sul Nasdaq Capital Market.

Il reverse split ridurrà le azioni in circolazione da circa 31.062.581 a 1.242.504. Le percentuali di proprietà degli azionisti rimarranno invariate, ad eccezione delle azioni frazionarie. La suddivisione regolerà proporzionalmente il numero di azioni emettibili tramite premi azionari e warrant, inclusi i loro prezzi di esercizio.

Questa mossa strategica mira a garantire la conformità con il requisito di prezzo minimo di offerta di Nasdaq di $1,00 per azione e ad attrarre una base di investitori più ampia. Gli azionisti hanno approvato la suddivisione in un incontro speciale del 15 gennaio 2025, concedendo al Consiglio la discrezionalità per un rapporto tra 1 per 2 e 1 per 240.

Virpax Pharmaceuticals (NASDAQ: VRPX) ha anunciado una división inversa de acciones de 1 por 25 que entrará en vigor el 20 de marzo de 2025. Las acciones ordinarias de la compañía comenzarán a cotizar en una base ajustada el 21 de marzo de 2025, manteniendo su símbolo VRPX en el Nasdaq Capital Market.

La división inversa reducirá las acciones en circulación de aproximadamente 31,062,581 a 1,242,504. Los porcentajes de propiedad de los accionistas permanecerán sin cambios, excepto por las acciones fraccionarias. La división ajustará proporcionalmente el número de acciones que se pueden emitir a través de premios de capital y warrants, incluidos sus precios de ejercicio.

Este movimiento estratégico tiene como objetivo cumplir con el requisito de precio mínimo de oferta de Nasdaq de $1.00 por acción y atraer una base de inversores más amplia. Los accionistas aprobaron la división en una reunión especial el 15 de enero de 2025, otorgando a la Junta discreción para un ratio entre 1 por 2 y 1 por 240.

Virpax Pharmaceuticals (NASDAQ: VRPX)는 2025년 3월 20일부터 시행되는 1대 25 비율의 주식 분할을 발표했습니다. 회사의 보통주는 2025년 3월 21일부터 분할 조정된 기준으로 거래를 시작하며, Nasdaq Capital Market에서 VRPX 기호를 유지합니다.

이번 비율 조정으로 유통 주식 수는 약 31,062,581주에서 1,242,504주로 줄어듭니다. 주주 소유 비율은 분수 주식을 제외하고는 변하지 않습니다. 이 분할은 자본 보상 및 워런트를 통해 발행 가능한 주식 수를 비례적으로 조정하며, 이들의 행사 가격도 포함됩니다.

이 전략적 조치는 Nasdaq의 최소 입찰가 요구 사항인 주당 $1.00을 충족하고 더 넓은 투자자 기반을 유치하는 것을 목표로 합니다. 주주들은 2025년 1월 15일 특별 회의에서 분할을 승인하였으며, 이사회에 1대 2에서 1대 240 사이의 비율에 대한 재량을 부여했습니다.

Virpax Pharmaceuticals (NASDAQ: VRPX) a annoncé un regroupement d'actions de 1 pour 25 qui entrera en vigueur le 20 mars 2025. Les actions ordinaires de la société commenceront à être négociées sur une base ajustée à partir du 21 mars 2025, tout en conservant son symbole VRPX sur le Nasdaq Capital Market.

Le regroupement réduira le nombre d'actions en circulation d'environ 31 062 581 à 1 242 504. Les pourcentages de propriété des actionnaires resteront inchangés, sauf pour les actions fractionnaires. Le regroupement ajustera proportionnellement le nombre d'actions pouvant être émises par le biais de primes en actions et de warrants, y compris leurs prix d'exercice.

Ce mouvement stratégique vise à se conformer à l'exigence de prix minimum de Nasdaq de 1,00 $ par action et à attirer une base d'investisseurs plus large. Les actionnaires ont approuvé le regroupement lors d'une réunion spéciale le 15 janvier 2025, accordant au Conseil la discrétion pour un ratio compris entre 1 pour 2 et 1 pour 240.

Virpax Pharmaceuticals (NASDAQ: VRPX) hat einen 1-zu-25 Reverse-Split angekündigt, der am 20. März 2025 in Kraft tritt. Die Stammaktien des Unternehmens werden ab dem 21. März 2025 auf einer nach dem Split angepassten Basis gehandelt, wobei das Symbol VRPX an der Nasdaq Capital Market beibehalten wird.

Der Reverse-Split wird die ausstehenden Aktien von etwa 31.062.581 auf 1.242.504 reduzieren. Die Eigentumsanteile der Aktionäre bleiben unverändert, mit Ausnahme von Bruchanteilen. Der Split wird die Anzahl der durch Aktienoptionen und Warrants ausgebbaren Aktien proportional anpassen, einschließlich ihrer Ausübungspreise.

Dieser strategische Schritt zielt darauf ab, die Einhaltung der Mindestgebotsanforderung von Nasdaq von 1,00 USD pro Aktie zu erreichen und eine breitere Investorenbasis anzuziehen. Die Aktionäre genehmigten den Split in einer außerordentlichen Sitzung am 15. Januar 2025 und erteilten dem Vorstand die Ermächtigung für ein Verhältnis zwischen 1 zu 2 und 1 zu 240.

Positive
  • Strategic move to maintain Nasdaq listing compliance
  • Potential to attract broader institutional and retail investor base
  • Stockholder approval obtained for the corporate action
Negative
  • Significant reduction in total outstanding shares may impact stock liquidity
  • Cash payments for fractional shares could result in forced partial position liquidation for some investors

Insights

Virpax's announced 1-for-25 reverse stock split represents a significant defensive financial maneuver primarily aimed at maintaining Nasdaq compliance. With shares currently trading at $0.13, this action will mathematically boost the share price to approximately $3.25 - just enough to clear Nasdaq's $1.00 minimum bid requirement.

The magnitude of this consolidation is particularly noteworthy. By reducing outstanding shares from 31.06 million to 1.24 million, management is implementing a dramatic solution that suggests underlying financial challenges. While reverse splits don't fundamentally change company value (market cap remains around $3.58 million), they typically signal financial distress rather than strength.

This maneuver buys Virpax time, but doesn't address the fundamental business challenges that drove the share price below Nasdaq requirements in the first place. For pharmaceutical companies with promising pipelines, such dramatic share consolidations are typically avoidable. The extremely small post-split market capitalization will continue limiting institutional investor interest despite management's stated intentions.

Most concerning is the timing and scale - stockholders granted the board authority for a split ratio between 1-for-2 and 1-for-240 in January, with management ultimately selecting a ratio (1-for-25) in the higher range, suggesting urgency in addressing compliance issues. The post-split share price will provide minimal cushion above minimum requirements, potentially necessitating additional defensive actions if business fundamentals don't improve.

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 (“Effective Time”). The new CUSIP number for the Common Stock following the reverse split will be 928251305.

At a special meeting of stockholders held on January 15, 2025 (the “Special Meeting”), the Company’s stockholders granted the Company’s Board of Directors (the “Board”) the discretion to effect a reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-2 and not more than 1-for-240, with such ratio to be determined by the Board. Following the Special Meeting, the final ratio of 1-for-25 was recently approved by the Board.

The 1-for-25 reverse stock split will proportionally reduce the number of outstanding shares of Common Stock from approximately 31,062,581 shares to approximately 1,242,504 shares and the ownership percentage of each shareholder will remain unchanged other than as a result of fractional shares. Proportional adjustments will be made to the number of shares of Common Stock issuable upon exercise or conversion of the Company’s outstanding equity awards and warrants, as well as the applicable exercise price. There will be no change to the total number of authorized shares of Common Stock as set forth in the Amended and Restated Certificate of Incorporation of the Company. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record, whose shares are held with the Company’s transfer agent, VStock Transfer, may direct questions to VStock Transfer at (212) 828-8436 or action@vstocktransfer.com.

The reverse split is intended to bring the Company into compliance with the minimum bid price requirement for maintaining the listing of its Common Stock on the Nasdaq Capital Market, and to make the bid price more attractive to a broader group of institutional and retail investors. The Nasdaq Capital Market requires, among other things, that a listed company’s common stock maintain a minimum bid price of at least $1.00 per share.

The Company’s transfer agent, VStock Transfer, LLC, which is also acting as the paying agent for the reverse split, will provide instructions to stockholders regarding the process for exchanging stock certificates. Any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) shall be entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the reverse split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the Nasdaq for the ten days preceding the Effective Time.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking partners for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit https://www.virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.

Forward-Looking Statements

This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the additional capital which will be necessary to complete studies and clinical trials that the Company plans to initiate and other factors listed under “Risk Factors” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:

info@virpaxpharma.com

Source: Virpax Pharmaceuticals, Inc.

FAQ

When will the Virpax Pharmaceuticals (VRPX) 1-for-25 reverse stock split take effect?

The reverse stock split will take effect at 12:01 a.m. Eastern Time on March 20, 2025, with split-adjusted trading beginning March 21, 2025.

How many VRPX shares will be outstanding after the reverse stock split?

The number of outstanding shares will reduce from approximately 31,062,581 to 1,242,504 following the 1-for-25 reverse split.

What happens to fractional shares in the VRPX reverse stock split?

Holders of fractional shares will receive cash payments based on the average closing price of VRPX stock for the ten days preceding the effective time.

Why is Virpax Pharmaceuticals (VRPX) implementing a reverse stock split?

The reverse split aims to comply with Nasdaq's minimum bid price requirement of $1.00 per share and attract a broader group of institutional and retail investors.
Virpax Pharmaceuticals Inc

NASDAQ:VRPX

VRPX Rankings

VRPX Latest News

VRPX Stock Data

198.80k
1.23M
1.13%
0.47%
3.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERWYN